リウマチ性関節炎シノビオサイトにおけるPI3K/ AKT/ mTOR経路の薬理学的抑制:体系的レビューとメタ解析 (臨床前)
Tatiana Bobkova1,2, Artem Bobkov3, Yang Li1,4
1Department of Rheumatology and Immunology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Pharmaceuticals (Basel, Switzerland)
|August 28, 2025
まとめ
PI3K/ AKT/ mTOR経路を標的にすると,リウマチ性関節炎における線維細胞のようなシノビオサイト増殖と炎症が著しく減少します. この経路は有効な治療目標であり,p- AKTとp- mTORは重要な応答マーカーとして機能する.
科学分野:
- 分子生物学
- 免疫学
- 薬理学について
背景:
- PI3K/AKT/mTOR経路の構成的活性化が,リウマチ性関節炎 (RA) での繊維細胞のような攻撃的シノビオサイト (FLS) 行動を引き起こします.
- RAにおけるPI3K/AKT/mTOR経路の抑制に関するin vitroデータの定量合成は欠けている.
研究 の 目的:
- 系統的にPI3K/AKT/mTOR経路阻害剤のRA-FLSの増殖,アポトーシス,移住,サイトカイン分泌,および重要なシグナル分子の効果をレビューし,メタ分析する.
- 不同性を評価し,刺激の種類,細胞源,抑制剤のクラスを含む治療効果の調節剤を特定する.
主な方法:
- 2025年5月までのPubMed,Europe PMC,コクラン図書館の体系的な文献検索
- 2人の独立した審査員によるデータ抽出と品質評価
- シディク・ジョンクマンモデルとハルトング・ナップ信頼区間を用いた標準化された平均差のランダム効果メタ解析 (ヘッジズg).
主要な成果:
- PI3K/ AKT/ mTORの阻害により,RA- FLSの増殖 (g = - 5. 1),IL- 6 (g = - 11. 1) およびIL- 8 (g = - 6. 5) の分泌が著しく減少し,同時にアポトーシスが増加した (g = + 2. 7).
- 大半のアウトカムでは,低~中程度の異質性 (I2 ≤35%) で大きな効果を示した.
- リン酸化AKT (p- AKT) とリン酸化mTOR (p- mTOR) レベルは,経路の阻害と機能的変化を確実に反映した.
結論:
- PI3K/ AKT/ mTOR経路の標的化された阻害は,RA- FLSの攻撃的で炎症性の表型を効果的に抑制する.
- PI3K/ AKT/ mTOR軸はRAにおける有効な治療目標である.
- p- AKTとp- mTORは,パーソナライズされた治療戦略をサポートし,治療反応を評価するための信頼性の高い薬動学的マーカーです.
関連する概念動画
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K


